title: The role of ceramide of human macrophage gangliosides in activation of human macrophages.
abstract: Gangliosides of macrophages have immunoregulatory and structural attributes, distinct from neural gangliosides. We previously produced a monoclonal antibody to human macrophage gangliosides (HMG; mAb25F4), which inhibited macrophage migration and recognized a surface-accessible epitope. We investigated expanded immunoregulatory properties and molecular domains for antibody recognition. mAb25F4 directly induced human macrophage production of proinflammatory cytokines, interleukin-1beta, and tumor necrosis factor alpha. Conditions were established for selective, reversible depletion of HMG with D-threo-(R,R)-1-phenyl-2-decanoyl-amino-3-morpholine-1-propanol. mAb25F4 had diminished recognition for ganglioside-depleted macrophages, which was restored with regeneration of gangliosides. Although desialylation of HMG did not impair mAb25F4 recognition, enzymatic cleavage of ceramide abolished antibody binding. Antibody recognition was specific for the ceramide fraction, with preferential recognition for ceramide of HMG and murine macrophage gangliosides and limited recognition for neural tissue ceramide and gangliosides. This study underscores the importance of structurally distinct ceramide of macrophage gangliosides as a critical domain for ganglioside-mediated activation of human macrophages.
authors.affiliation: Infectious Diseases Section, Department of Veterans Affairs Western New York Healthcare System, State University of New York at Buffalo, School of Medicine, 14215, USA. berenson@acsu.buffalo.edu
authors.forename: Charles S
authors.initials: CS
authors.lastname: Berenson
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Gallery
authors.forename: Jane M
authors.initials: JM
authors.lastname: Smigiera
authors.forename: Robin H
authors.initials: RH
authors.lastname: Rasp
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000918:Antibody Specificity; D002518:Ceramides / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005732:Gangliosides / Q000276:immunology* / Q000378:metabolism; D006017:Glycolipids / Q000032:analysis; D006026:Glycoside Hydrolases / Q000494:pharmacology; D006801:Humans; D008262:Macrophage Activation / Q000187:drug effects / Q000502:physiology*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D009025:Morpholines / Q000494:pharmacology; D009439:Neuraminidase / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D002518:Ceramides; D016207:Cytokines; D004791:Enzyme Inhibitors; D005732:Gangliosides; D006017:Glycolipids; D009025:Morpholines; C033110:RV 538; D006026:Glycoside Hydrolases; C051111:ceramide glycanase; D009439:Neuraminidase